RU2018125431A3 - - Google Patents

Download PDF

Info

Publication number
RU2018125431A3
RU2018125431A3 RU2018125431A RU2018125431A RU2018125431A3 RU 2018125431 A3 RU2018125431 A3 RU 2018125431A3 RU 2018125431 A RU2018125431 A RU 2018125431A RU 2018125431 A RU2018125431 A RU 2018125431A RU 2018125431 A3 RU2018125431 A3 RU 2018125431A3
Authority
RU
Russia
Application number
RU2018125431A
Other languages
Russian (ru)
Other versions
RU2789884C2 (ru
RU2018125431A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018125431A publication Critical patent/RU2018125431A/ru
Publication of RU2018125431A3 publication Critical patent/RU2018125431A3/ru
Application granted granted Critical
Publication of RU2789884C2 publication Critical patent/RU2789884C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018125431A 2015-12-18 2016-12-16 Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения RU2789884C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18
JP2015-247070 2015-12-18
PCT/JP2016/087487 WO2017104783A1 (en) 2015-12-18 2016-12-16 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Publications (3)

Publication Number Publication Date
RU2018125431A RU2018125431A (ru) 2020-01-20
RU2018125431A3 true RU2018125431A3 (ko) 2020-07-06
RU2789884C2 RU2789884C2 (ru) 2023-02-14

Family

ID=

Also Published As

Publication number Publication date
JP6142069B1 (ja) 2017-06-07
CN115028721A (zh) 2022-09-09
SG11201610812WA (en) 2017-07-28
MX2018007145A (es) 2018-08-15
AU2016372934B2 (en) 2023-10-05
MY189425A (en) 2022-02-10
TW201808992A (zh) 2018-03-16
KR20170085028A (ko) 2017-07-21
KR20180085711A (ko) 2018-07-27
HK1254755A1 (zh) 2019-07-26
KR102501335B1 (ko) 2023-02-17
JP2017148069A (ja) 2017-08-31
TWI749057B (zh) 2021-12-11
RU2018125431A (ru) 2020-01-20
KR20240058997A (ko) 2024-05-03
CN108473562B (zh) 2022-06-17
JP2022097485A (ja) 2022-06-30
TWI605057B (zh) 2017-11-11
BR112018011073A2 (pt) 2018-11-21
AU2016372934A1 (en) 2018-05-10
EP3390443A4 (en) 2019-11-13
KR20230027321A (ko) 2023-02-27
CA3002422A1 (en) 2017-06-22
TW202231662A (zh) 2022-08-16
CA3002422C (en) 2024-04-16
SG10201707267RA (en) 2017-10-30
JP7053164B2 (ja) 2022-04-12
PH12018501280A1 (en) 2019-01-28
TW201726718A (zh) 2017-08-01
KR101820637B1 (ko) 2018-01-19
JP2017112997A (ja) 2017-06-29
WO2017104783A1 (en) 2017-06-22
CN108473562A (zh) 2018-08-31
EP3390443A1 (en) 2018-10-24
AR107078A1 (es) 2018-03-21
EA201891420A1 (ru) 2019-02-28
JP2024023427A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
BR122021025194A2 (ko)
BR112018005646A2 (ko)
RU2018125431A3 (ko)
BR0009373B1 (ko)
BR0000695B1 (ko)
CN303138758S (ko)
CN303119563S (ko)
CN303115415S (ko)
CN303107399S (ko)
CN303102663S (ko)
BR0002402B1 (ko)
CN303097126S (ko)
BR0001810B1 (ko)
CN303096229S (ko)
CN303094804S (ko)
CN303089687S (ko)
CN303076390S (ko)
BR0318347B1 (ko)
BR0109490B1 (ko)
BR0108786B1 (ko)
BR0010150B1 (ko)
BR0009994B1 (ko)
BR0009942B1 (ko)
BR0009761B1 (ko)
BR0009757B1 (ko)